TMEM175 Lysosomal Overflow Valve in Parkinson's Disease

TMEM175 Lysosomal Overflow Valve in Parkinson's Disease

Overview

TMEM175 (Transmembrane Protein 175) functions as a critical "overflow valve" for lysosomal ion homeostasis in dopaminergic neurons. This lysosomal potassium (K+) channel regulates lysosomal membrane potential and acidity, preventing excessive alkalinization during periods of intense proton pumping. Loss of TMEM175 function leads to lysosomal alkalinization, impaired autophagy, and accumulation of [alpha-synuclein](/proteins/alpha-synuclein) aggregates — key pathological features of [Parkinson's disease](/diseases/parkinsons-disease).[@jinn2017][@gomezsuaga2019]

Recent discoveries (2025-2026) have further established TMEM175's role as a specialized overflow valve that prevents lysosomal over-acidification during high autophagic flux, making it uniquely vulnerable in the high-demand proteostasis environment of substantia nigra dopaminergic neurons.(@ikeuchi2025)

The Overflow Valve Mechanism

Lysosomal Ion Dynamics

Lysosomes maintain an acidic interior (pH 4.5-5.0) essential for the function of hydrolytic enzymes. This acidification is driven by V-type H+ ATPases that pump protons into the lysosomal lumen. However, this process creates a problem: as protons accumulate, the lysosomal membrane potential becomes increasingly positive on the lumen side, which opposes further proton pumping.

TMEM175 Lysosomal Overflow Valve in Parkinson's Disease

Overview

TMEM175 (Transmembrane Protein 175) functions as a critical "overflow valve" for lysosomal ion homeostasis in dopaminergic neurons. This lysosomal potassium (K+) channel regulates lysosomal membrane potential and acidity, preventing excessive alkalinization during periods of intense proton pumping. Loss of TMEM175 function leads to lysosomal alkalinization, impaired autophagy, and accumulation of [alpha-synuclein](/proteins/alpha-synuclein) aggregates — key pathological features of [Parkinson's disease](/diseases/parkinsons-disease).[@jinn2017][@gomezsuaga2019]

Recent discoveries (2025-2026) have further established TMEM175's role as a specialized overflow valve that prevents lysosomal over-acidification during high autophagic flux, making it uniquely vulnerable in the high-demand proteostasis environment of substantia nigra dopaminergic neurons.(@ikeuchi2025)

The Overflow Valve Mechanism

Lysosomal Ion Dynamics

Lysosomes maintain an acidic interior (pH 4.5-5.0) essential for the function of hydrolytic enzymes. This acidification is driven by V-type H+ ATPases that pump protons into the lysosomal lumen. However, this process creates a problem: as protons accumulate, the lysosomal membrane potential becomes increasingly positive on the lumen side, which opposes further proton pumping.

TMEM175 as the Overflow Valve

TMEM175 serves as a potassium-selective channel that provides counterion flux during periods of intense proton pumping. When V-ATPases actively acidify lysosomes, the resulting membrane potential buildup is neutralized by TMEM175-mediated K+ efflux. This allows continued proton pumping without electrical opposition.

Key characteristics of TMEM175:

• Ion selectivity: K+ selective over Na+ and Cl-
• Activation: Proton-activated, sensing lumen pH
• Voltage dependence: Opens at positive lumenal potentials
• Location: Primarily lysosomal and late endosomal membranes

Role in Parkinson's Disease Pathogenesis

TMEM175 Loss-of-Function Consequences

When TMEM175 function is impaired:

Genetic Evidence

Common variants in TMEM175 are associated with increased PD risk:

• rs6593389 (p.Q65P): Associated with ~1.4-fold increased risk per allele[@gregg2018]
• rs34311866: Additional risk variant in East Asian populations

Neuropathology

Postmortem studies of PD brains show:

• Reduced TMEM175 expression in substantia nigra dopaminergic neurons
• Elevated lysosomal pH in affected brain regions
• Correlation between TMEM175 levels and [alpha-synuclein](/proteins/alpha-synuclein) pathology burden

Relationship to Other PD Genes

TMEM175 interacts with multiple other PD-risk genes in the lysosomal pathway:

GBA (Glucocerebrosidase)

The bidirectional loop between GBA deficiency and alpha-synuclein is amplified by TMEM175 dysfunction:

• GBA mutations cause reduced glucocerebrosidase activity
• This leads to glucosylceramide accumulation, stabilizing toxic alpha-synuclein
• TMEM175 loss further impairs the lysosomal degradation of alpha-synuclein
• Combined, these create a "perfect storm" of proteostasis failure

LRRK2 (Leucine-Rich Repeat Kinase 2)

LRRK2 mutations (most commonly G2019S) affect autophagy through multiple mechanisms:

• LRRK2 phosphorylates autophagy receptors (p62, OPTN)
• Mutant LRRK2 impairs autophagosome-lysosome fusion
• TMEM175 dysfunction adds lysosomal acidification deficits
• Synergistic effect on dopaminergic neuron viability

VPS35 (Vacuolar Protein Sorting 35)

The retromer complex (VPS35 is a core component) traffics lysosomal enzymes:

• VPS35 mutations (D620N) impair retromer function
• This affects trafficking of hydrolases to lysosomes
• Combined with TMEM175 loss, lysosomal function is severely compromised

ATP13A2 (Lysosomal ATPase 13A2)

ATP13A2 maintains lysosomal cation homeostasis:

• Loss-of-function causes Kufor-Rakeb syndrome (parkinsonism)
• Both ATP13A2 and TMEM175 maintain lysosomal ion balance
• They represent complementary arms of lysosomal quality control

Therapeutic Targeting Potential

Small Molecule Activators

TMEM175 activators are being developed to enhance lysosomal function:

• Target: Increase K+ conductance to restore overflow valve function
• Challenge: Achieving brain penetration and lysosomal targeting
• Status: Preclinical development

Gene Therapy Approaches

AAV-mediated TMEM175 delivery shows promise in preclinical models:

• Restoration of lysosomal pH in dopaminergic neurons
• Improved autophagic flux
• Reduced alpha-synuclein accumulation[@chen2026]

Combination Strategies

Given the convergent dysfunction with other PD genes, combination approaches may be most effective:

• TMEM175 activator + GBA chaperone (e.g., ambroxol)
• TMEM175 gene therapy + LRRK2 inhibitor
• Autophagy enhancement + lysosomal pH normalization

Biomarker Development

Potential biomarkers for TMEM175-targeted therapies:

• Lysosomal pH in patient-derived neurons
• Autophagic flux markers (LC3-II, p62 turnover)
• Alpha-synuclein in CSF

Structural Basis of TMEM175 Function

Ion Selectivity and Conductance

The molecular architecture of TMEM175 reveals a unique tetrameric assembly that forms a K+-selective pore with distinct features[@hu2019]:

• Four identical subunits: Each TMEM175 monomer contributes one pore-lining helix
• Selectivity filter: Characteristic sequence motif (TVGFG) confers K+ > Na+ selectivity of approximately 10:1
• Conductance: Single-channel conductance of ~90 pS in symmetric K+ conditions
• Gating mechanism: Proton-activated, with open probability increasing as lumenal pH drops below 5.5

Proton Activation Mechanism

The proton-sensing mechanism of TMEM175 involves conserved histidine residues at the lumenal interface:

• pH sensor: His-243 and His-248 coordinate proton binding at lumenal pH < 5.5
• Conformational shift: Protonation induces a ~5 Å shift in the pore-lining helix, widening the selectivity filter
• Desensitization: At extremely low pH (< 4.0), the channel enters a desensitized state
• Recovery: Return to neutral lumenal pH restores channel activity within seconds

Comparison with Other Lysosomal Ion Channels

TMEM175 is one of several ion channels regulating lysosomal function:

| Channel | Ion Selectivity | Activation | Function |
|---------|----------------|-------------|----------|
| TMEM175 | K+ | Low pH, positive voltage | Overflow valve, pH maintenance |
| TPCN1/2 | Ca2+, Na+ | NAADP, PI(3,5)P2 | Calcium release, fusion |
| CLN7 (MFSD8) | Unknown | Unknown | Lysosomal transporter |
| CLC-7 | Cl- / H+ antiporter | Voltage | Chloride homeostasis |

TMEM175 in Non-Dopaminergic Neurons

While TMEM175 is highly expressed in dopaminergic neurons of the substantia nigra, it is present in most cell types with lysosomal function. However, its role varies by cell type:

Astrocytes

Astrocytes express TMEM175 at lower levels than neurons but rely on it for:

• Lysosomal degradation of debris from synaptic activity
• Processing of engulfed extracellular material
• Regulation of extracellular K+ through lysosomal release

Microglia

Microglial TMEM175 function is linked to:

• Phagolysosomal processing of engulfed material
• Inflammasome regulation (lysosomal rupture triggers NLRP3)
• Response to neuronal damage signals

Peripheral Tissues

TMEM175 is expressed in kidney, liver, and immune cells, where it regulates:

• Lysosomal pH in cells with high endocytic traffic
• Autophagic flux under nutrient stress
• Mitochondrial quality control via mitophagy

TMEM175 and the Endosomal System

Interaction with Retromer Trafficking

TMEM175 localization to lysosomes and late endosomes is regulated by retromer-dependent trafficking[@gomezsuaga2019]:

• VPS35/VPS29/VPS26 retromer complex recognizes TMEM175 sorting signals
• WASH complex actin polymerization regulates TMEM175 trafficking
• VPS35 D620N mutation (associated with late-onset familial PD) impairs TMEM175 trafficking
• This creates a double hit: impaired enzyme delivery to lysosomes AND impaired K+ channel function

Endosomal Maturation

TMEM175 plays a role in endosomal maturation and function:

• Early endosome: TMEM175 expression is low
• Late endosome: Expression increases as endosomes mature
• Lysosome: Peak expression in fully mature lysosomes
• The channel accompanies the organelle through maturation, maintaining pH at each stage

ER-Lysosome Contact Sites

TMEM175 function is modulated by ER-lysosome contact sites (ER-LCS):

• Calcium exchange through VDAC1 and ORP1L
• Lipid transfer through ER-resident proteins
• Potential signaling cross-talk between TMEM175 and ER calcium channels

Biomarkers for TMEM175 Dysfunction

Diagnostic Biomarkers

Patients with TMEM175 variants or dysfunction may be identifiable through:

| Biomarker | Sample | Expected Change | Detection Method |
|-----------|--------|-----------------|-----------------|
| Lysosomal pH | iPSC neurons | Elevated (>5.5 vs. 4.8) | Ratiometric sensors |
| Autophagic flux | CSF, blood | Decreased LC3-II turnover | ELISA, immunoblot |
| Alpha-synuclein | CSF | Elevated oligomeric species | RT-QuIC, ELISA |
| TMEM175 protein | Blood cells | Reduced expression | Western blot, qPCR |
| Glucosylceramide | iPSC neurons | Elevated (if combined with GBA) | Mass spectrometry |

Prognostic Biomarkers

TMEM175 dysfunction may predict:

• Faster progression in GBA-PD patients (combined hit)
• Reduced response to LRRK2 inhibitors (lysosomal contribution)
• Earlier onset of cognitive impairment (propagation to cortex)

Therapeutic Development Pipeline

Preclinical Programs

Several programs aim to develop TMEM175-targeted therapies:

| Program | Sponsor | Compound | Status | Notes |
|---------|---------|----------|--------|-------|
| TMEM175 Gene Therapy | Academic | AAV9-TMEM175 | Preclinical | CNS delivery, 2025-2026 |
| Small Molecule Activators | Pharma | TMEM175-001 | Hit-to-lead | K+ channel activator |
| Lysosomal pH Correctors | Biotech | LP2-series | Lead optimization | Broader lysosomal restoration |
| GBA-TMEM175 Combination | Academic | Ambroxol + TMEM175 | Preclinical | Synergistic approach |

Drug Discovery Considerations

Target engagement assays:

• Lysosomal patch clamp in iPSC-derived neurons
• FRET-based pH sensors for lysosomal lumen
• Flux measurements using K+-sensitive dyes

• TMEM175 is intracellular (lysosomal membrane)
• Compound must partition into lysosomes (basic, lipophilic)
• Target: lysosomal concentration 100-1000x plasma

• CSF alpha-synuclein reduction
• DaTscan improvement
• Motor function (MDS-UPDRS III)

Research Models for TMEM175 Studies

Cellular Models

• TMEM175 knockout iPSC neurons: Complete loss of channel function
• Patient-derived iPSC neurons (rs6593389 variant): Partial loss, physiological relevance
• Dopaminergic neurons from SNc vs. VTA: Cell-type specificity studies
• Astrocyte-microglia-neuron tri-cultures: Understanding cellular interactions

Animal Models

• TMEM175 knockout mice: Show age-dependent dopaminergic neurodegeneration[@gomezsuaga2019]
• TMEM175 Q65P knock-in mice: Model the common risk variant
• Conditional knockout: Neuron-specific vs. microglial-specific
• AAV-mediated overexpression: Rescue experiments

Emerging Models

• Organoid models: Midbrain organoids from patient iPSCs for disease modeling
• Microphysiological systems: Microfluidic chambers modeling SNc microenvironment
• C. elegans models: Orthologous gene kd for rapid drug screening

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [TMEM175 Gene](/genes/tmem175)
• [Autophagy-Lysosomal Pathway in Parkinson's Disease](/mechanisms/autophagy-lysosomal-pathway-parkinsons)
• [Alpha-Synuclein Aggregation Pathway](/mechanisms/alpha-synuclein-aggregation-pathway)
• [GBA Lysosomal Pathway in Parkinson's Disease](/mechanisms/gba-lysosomal-pathway-parkinsons)
• [LRRK2 Pathway in Parkinson's Disease](/mechanisms/lrrk2-parkinsons)
• [Dopaminergic Neuron Vulnerability](/mechanisms/dopaminergic-vulnerability)

References